Contineum's J&J-partnered MS drug fails to improve vision in phase 2
#Contineum Therapeutics’#receptor antagonist#multiple sclerosis#drug fails#common form
Life Science News
Latest updates from the biotech and pharma world
FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process
#review process#pilot communication#comms program#communication program#FDA
GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement
#GSK Tesaro#Jemperli agreement#GSK subsidiary#subsidiary Tesaro#life span
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off
#Nurix Therapeutics#Nurix trims#BTK degrader#cancer asset#lead BTK
Roche inks $200M-plus licensing pact for Freenome's cancer screening blood tests
#Roche inks#licensing pact#million equity#Freenome cancer#blood tests
Chutes & Ladders—Gilead abruptly parts ways with general counsel
#Deborah Telman#filing Nov.#Gilead abruptly#general counsel#affairs Deborah
CDC instructs researchers to end all monkey studies by year-end: Science
#Science reported#CDC instructs#instructs researchers#instructing scientists#research involving
Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
#Dayra Therapeutics#Versant Ventures#oral macrocyclic#macrocyclic peptide#Versant Dayra
J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2
#Alzheimer hope#anti-tau antibody#antibody posdinemab#hope fades#disease drug
Abbott to replace certain FreeStyle Libre 3 CGMs after incorrect readings and death reports
#FreeStyle Libre#million FreeStyle#death reports#Libre#incorrect readings
Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program
#Sprint Bioscience#cancer program#Swedish biotech#Gilead hatches#million upfront
Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease
#Alzheimer disease#Novo Nordisk#trial misses#Novo shares#Alzheimer
'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference
#Jefferies conference#Global uncertainties#upbeat Jefferies#cautious optimism#dampen upbeat
Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
#Bayer asundexian#reviving hopes#FXIa class#significantly reduced#potentially blockbuster
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
#Sarepta-licensed RNA#RNA medicine#Sarepta shares#enrollment target#Arrowhead snares
Solventum to buy Acera Surgical for up to $850M, repurchase $1B in stock
#Acera Surgical#buy Acera#specialist Acera#years ago#major acquisition
J&J MedTech bolsters stroke R&D programs in Ireland
#MedTech bolsters#bolsters stroke#innovation center#completed earlier#hreflang